학술논문

A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory (R/ R) NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Document Type
Journal
Source
JOURNAL OF THORACIC ONCOLOGY; MAR 2023, 18 3, pE14-pE14, 1p. Supplement: S
Subject
Language
English
ISSN
15561380